Anti-cancer potential of zerumbone in cancer and glioma: current trends and future perspectives

Med Oncol. 2024 Apr 23;41(5):125. doi: 10.1007/s12032-024-02327-3.

Abstract

Plant-derived immunomodulators and antitumor factors have appealed lots of attention from natural product scientists for their efficiency and safety and their important contribution to well-designed targeted drug action and delivery mechanisms. Zerumbone (ZER), the chief component of Zingiber zerumbet rhizomes, has been examined for its wide-spectrum in the treatment of multi-targeted diseases. The rhizomes have been used as food flavoring agents in numerous cuisines and in flora medication. Numerous in vivo and in vitro experiments have prepared confirmation of ZER as a potent immunomodulator as well as a potential anti-tumor agent. This review is an interesting compilation of all the important results of the research carried out to date to investigate the immunomodulatory and anticancer properties of ZER. The ultimate goal of this comprehensive review is to supply updated information and a crucial evaluation on ZER, including its chemistry and immunomodulating and antitumour properties, which may be of principal importance to supply a novel pathway for subsequent investigation to discover new agents to treat cancers and immune-related sickness. In addition, updated information on the toxicology of ZER has been summarized to support its safety profile.

Keywords: Anti-tumor; Glioma; Immunomodulators; Zerumbone.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Agents, Phytogenic / pharmacology
  • Antineoplastic Agents, Phytogenic / therapeutic use
  • Glioma* / drug therapy
  • Humans
  • Neoplasms / drug therapy
  • Sesquiterpenes* / pharmacology
  • Sesquiterpenes* / therapeutic use

Substances

  • zerumbone
  • Sesquiterpenes
  • Antineoplastic Agents, Phytogenic
  • Antineoplastic Agents